CHANGES IN P-SELECTIN LEVEL IN BLOOD SERUM IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
DOI:
https://doi.org/10.11603/1811-2471.2020.v.i2.11337Keywords:
non-alcoholic fatty liver disease, insulin resistance, diabetes mellitus, P-selectinAbstract
Non-alcoholic fatty liver disease (NAFLD) covers a range of diseases closely related to metabolic risk factors. As a result of insulin resistance (IR) in patients with metabolic syndrome, diabetes mellitus (DM) type 2, NAFLD, is forming endothelial dysfunction (DE).
The aim – to investigate the peculiarities of changes in the level of P-selectin in the serum of patients with NAFLD depending on the presence or absence of type 2 diabetes and malnutrition.
Material and Methods. 104 patients with NAFLD were examined. Patients were distributed as follows: subgroup 1.1 included 22 patients with nonalcoholic fatty hepatosis (NAFH) and IR, subgroup 1.2 consisted of 30 patients with NAFH and type 2 diabetes; subgroup 2.1 included 26 patients with nonalcoholic steatohepatitis (NASH) and IR, and subgroup 2.2 consisted of 26 patients with NAST and type 2 diabetes. All examined patients underwent general clinical studies, as well as determination of serum P-selectin levels.
Results and Discussion. An increase in the level of P-selectin was found in all subgroups of patients examined by us. The stage of increase of its concentration in blood serum with progression of liver damage (from NAFH to NASH), as well as its combination with IR or type 2 diabetes was revealed. Therefore, the maximum level of P-selectin was determined in patients of subgroup 2.2 (445.81±9.13 ng/ml, p<0.01), and the minimum in patients of subgroup 1.1 (226.14±7.56 ng/ml, p<0.05).
Conclusions. In patients with NAFLD, an increase in serum P-selectin levels was found, with its maximum deviations from the norm in NASH in combination with type 2 diabetes and minimal changes in patients with NAFH and IR. In patients with NAFLD and carbohydrate metabolism disorders (type 2 diabetes or diabetes mellitus), the level of P-selectin increases in accordance with the increase in body weight index with maximum values in patients with grade II obesity.
References
Stepanov, Yu.M., Nedzvetskaya, N.V., Yagmur, V.B., & Klenina, I.A. (2018). Nealkoholna zhyrova khvoroba pechinky: osoblyvosti metabolichnykh zmin na riznykh etapakh rozvytku khvoroby [Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease]. Hastroenterolohiia – Gastroenterology, 52 (1), 13-18. DOI: 10.22141/2308-2097.52.1.2018.130772 [in Ukrainian].
Asrih, M., & Jornayvaz, F.R. (2013). Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology, 218 (3), 25-36. DOI: 10.1530/JOE-13-0201.
Zheng, C., & Zhenqi, L. (2015). Vascular function, insulin action and exercise: An intricate interplay. Trends Endocrinol. Metab., 26 (6), 297-304. DOI:10.1016/j.tem.2015.02.002
WHO: Global Database on Body Mass Index. Retrieved from: http://apps.who.int/bmi/index.jsp?introPage= intro_3.html
Celermajer, D.S., Sorensen, K.E., Bull, C., Robinson, J., & Deanfield, J.E. (1994). Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factor and their interaction. J. Am. Coll.Cariol., 24 (6), 1468-1474.
Hobzei, M.K., Hulchii, M.V., & Stepanenko, A.V. (2012). Unifikovanyi klinichnyi protocol pervynnoi ta vtorynnoi (spetsializovanoi) dopomohy [Unified clinical protocol for primary and secondary (specialized) medical care]. Kyiv. Retrieved from: http://ukrgastro.com.ua/klinichni-protokoli-ta-nastanovi/ [in Ukrainian].
Hobzei, M.K., Matyuha, L.F., & Netiazhenko, V.Z. (2012). Tsukrovyi diabet 2 typu. Adaptovana klinichna nastanova, zasnovana na dokazakh diabet 2 typu [Type 2 diabetes mellitus. Adapted clinical guideline based on evidence]. Kyiv. Retrieved from: http://ukrgastro.com.ua/klinichni-protokoli-ta-nastanovi/ [in Ukrainian].
